Summit Therapeutics (SMMT) competitors & alternatives
Health Care · NASDAQ
Summit Therapeutics (SMMT)'s top competitors and alternatives — its most similar public companies — include Bristol Myers Squibb (BMY), ASTRAZENECA PLC (AZN), BridgeBio Oncology Therapeutics, Inc. (BBOT), Exelixis (EXEL), CRESCENT BIOPHARMA INC (CBIO), COMPASS THERAPEUTICS (CMPX), IOVANCE BIOTHERAPEUTICS INC (IOVA), BLACK DIAMOND THERAPEUTICS INC (BDTX), CONTEXT THERAPEUTICS INC (CNTX), Genelux Corp (GNLX), ARRIVENT BIOPHARMA INC (AVBP) and WHITEHAWK THERAPEUTICS INC (WHWK). These are Summit Therapeutics's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top SMMT competitors & alternatives
-
Bristol Myers SquibbBMYHealth Care
Bristol Myers Squibb is a leading biopharmaceutical company specializing in advanced oncology, immunology, and cardiovascular therapies using diverse…
$60.76 (as of 2026-07-22) · market cap $124.9B
-
ASTRAZENECA PLCAZN
Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
$169.73 (as of 2026-07-22) · market cap $193.7B
-
BridgeBio Oncology Therapeutics, Inc.BBOTHealth Care
BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including…
$8.90 (as of 2026-07-22) · market cap $701M
-
ExelixisEXELHealth Care
Exelixis is a profitable oncology company commercializing the multi-kinase inhibitor cabozantinib across multiple cancer indications while advancing a pipeline…
$54.98 (as of 2026-07-22) · market cap $14.0B
-
CRESCENT BIOPHARMA INCCBIOHealth Care
Crescent Biopharma is a clinical-stage oncology company developing a novel PD-1 x VEGF bispecific antibody and a portfolio of antibody-drug conjugates to…
$15.83 (as of 2026-07-22) · market cap $615M
-
COMPASS THERAPEUTICSCMPXHealth Care
Compass Therapeutics is a clinical-stage oncology company developing a pipeline of bispecific and agonistic antibodies designed to treat solid tumors by…
$2.04 (as of 2026-07-22) · market cap $367M
-
IOVANCE BIOTHERAPEUTICS INCIOVAHealth Care
Iovance delivers Amtagvi, the first FDA-approved individualized TIL cell therapy for advanced melanoma, with a pipeline expanding to lung cancer and sarcoma…
$5.17 (as of 2026-07-22) · market cap $2.3B
-
BLACK DIAMOND THERAPEUTICS INCBDTXHealth Care
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey inhibitors designed to target families of oncogenic mutations across…
$1.83 (as of 2026-07-22) · market cap $106M
-
CONTEXT THERAPEUTICS INCCNTXHealth Care
Clinical-stage biopharmaceutical company developing T-cell engaging bispecific antibodies to treat solid tumors by redirecting immune cells against cancer…
$0.61 (as of 2026-07-22) · market cap $56M
-
Genelux CorpGNLXHealth Care
Genelux is a late clinical-stage biopharmaceutical company developing oncolytic vaccinia virus immunotherapies designed to selectively kill tumor cells and…
$2.96 (as of 2026-07-22) · market cap $131M
-
ARRIVENT BIOPHARMA INCAVBPHealth Care
Arrivent Biopharma is a clinical-stage oncology company advancing firmonertinib, an EGFR-targeted tyrosine kinase inhibitor for treating non-small cell lung…
$30.44 (as of 2026-07-22) · market cap $1.3B
-
WHITEHAWK THERAPEUTICS INCWHWKHealth Care
Clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) targeting validated tumor antigens with advanced linker-payload…
$3.99 (as of 2026-07-22) · market cap $216M
Not quite? Describe exactly what you want →
Peers are Summit Therapeutics's closest public companies by shared sub-industry, sector and business themes. See the full profile: Summit Therapeutics (SMMT).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.